Cambridge office
Exclusive: Charles Fuchs departs Roche to become Chief Medical Officer at Tubulis, steering ADC pipeline after $401M Series C
Charles Fuchs; Tubulis; Roche; Genentech; chief medical officer; antibody-drug conjugates; ADC pipeline; TUB-040; TUB-030; Series C financing; oncology; hematology; solid tumors; NaPi2b; 5T4; Cambridge office